I'm a technology entrepreneur. In 2024 I founded Conquest to develop a new therapeutic paradigm to tackle cancer.
Before that I spent a decade at ASAPP, which I founded in 2014 and ran until 2024. From time to time I invest in private technology companies and other asset classes.
I live in Montana. In addition to work, I enjoy flying and classical music.
Why the one-drug, one-target paradigm persists despite decades of evidence against it — and why a new one is needed.
The publishing lab we ran for a decade inside ASAPP — the work, the people, and where they went.